Clifford J Bailey

Summary

Affiliation: Aston University
Country: UK

Publications

  1. ncbi request reprint Sibutramine metabolites increase glucose transport by cultured rat muscle cells
    C J Bailey
    School of Life and Health Sciences, Aston University, Birmingham, UK, UK
    Int J Obes Relat Metab Disord 25:478-85. 2001
  2. ncbi request reprint Treating insulin resistance in type 2 diabetes with metformin and thiazolidinediones
    C J Bailey
    School of Life and Health Sciences, Aston University, Birmingham, UK
    Diabetes Obes Metab 7:675-91. 2005
  3. doi request reprint Metformin: effects on micro and macrovascular complications in type 2 diabetes
    Clifford J Bailey
    School of Life and Health Sciences, Aston University, Birmingham, UK
    Cardiovasc Drugs Ther 22:215-24. 2008
  4. doi request reprint Individualized glycaemic targets and pharmacotherapy in type 2 diabetes
    Clifford J Bailey
    Diabetes Research, School of Life and Health Sciences, Aston University, Birmingham, UK
    Diab Vasc Dis Res 10:397-409. 2013
  5. pmc Interpreting adverse signals in diabetes drug development programs
    Clifford J Bailey
    School of Life and Health Sciences, Aston University, Birmingham, UK
    Diabetes Care 36:2098-106. 2013
  6. pmc Dapagliflozin add-on to metformin in type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled 102-week trial
    Clifford J Bailey
    Life and Health Sciences, Aston University, Birmingham B4 7ET, UK
    BMC Med 11:43. 2013
  7. doi request reprint Dapagliflozin monotherapy in drug-naïve patients with diabetes: a randomized-controlled trial of low-dose range
    C J Bailey
    Life and Health Sciences, Aston University, Birmingham, UK
    Diabetes Obes Metab 14:951-9. 2012
  8. pmc Functional enhancement of electrofusion-derived BRIN-BD11 insulin-secreting cells after implantation into diabetic mice
    E L Davies
    School of Life and Health Sciences, Aston University, Birmingham, UK
    Int J Exp Diabetes Res 2:29-36. 2001
  9. ncbi request reprint Glucosamine-induced insulin resistance in L6 muscle cells
    C J Bailey
    School of Life and Health Sciences, Aston University, Birmingham, UK
    Diabetes Obes Metab 6:293-8. 2004
  10. ncbi request reprint Avandamet: combined metformin-rosiglitazone treatment for insulin resistance in type 2 diabetes
    C J Bailey
    School of Life and Health Sciences, Aston University, Birmingham, UK
    Int J Clin Pract 58:867-76. 2004

Collaborators

Detail Information

Publications55

  1. ncbi request reprint Sibutramine metabolites increase glucose transport by cultured rat muscle cells
    C J Bailey
    School of Life and Health Sciences, Aston University, Birmingham, UK, UK
    Int J Obes Relat Metab Disord 25:478-85. 2001
    ..CONCLUSIONS: Sibutramine metabolites can improve insulin-sensitive 2-deoxyglucose uptake by cultured muscle cells independently of SNRI effects...
  2. ncbi request reprint Treating insulin resistance in type 2 diabetes with metformin and thiazolidinediones
    C J Bailey
    School of Life and Health Sciences, Aston University, Birmingham, UK
    Diabetes Obes Metab 7:675-91. 2005
    ..Thus, metformin and thiazolidinediones can be used in combination to address the hyperglycaemia and vascular risk in type 2 diabetes...
  3. doi request reprint Metformin: effects on micro and macrovascular complications in type 2 diabetes
    Clifford J Bailey
    School of Life and Health Sciences, Aston University, Birmingham, UK
    Cardiovasc Drugs Ther 22:215-24. 2008
    ..This apparently vasoprotective effect appears to be independent of the blood glucose-lowering efficacy...
  4. doi request reprint Individualized glycaemic targets and pharmacotherapy in type 2 diabetes
    Clifford J Bailey
    Diabetes Research, School of Life and Health Sciences, Aston University, Birmingham, UK
    Diab Vasc Dis Res 10:397-409. 2013
    ..Individualizing therapeutic goals and treatments to meet glycaemic targets safely and without delay remains paramount, in addition to a wider programme of care to reduce cardiovascular risk factors and improve patient outcomes. ..
  5. pmc Interpreting adverse signals in diabetes drug development programs
    Clifford J Bailey
    School of Life and Health Sciences, Aston University, Birmingham, UK
    Diabetes Care 36:2098-106. 2013
    ..Thus, as information and experience accumulate with time, it should be accepted that benefit-risk deliberations will be refined, and adjustments to prescribing indications may become appropriate. ..
  6. pmc Dapagliflozin add-on to metformin in type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled 102-week trial
    Clifford J Bailey
    Life and Health Sciences, Aston University, Birmingham B4 7ET, UK
    BMC Med 11:43. 2013
    ..The present study is an extension that was undertaken to evaluate dapagliflozin as long-term therapy in this population...
  7. doi request reprint Dapagliflozin monotherapy in drug-naïve patients with diabetes: a randomized-controlled trial of low-dose range
    C J Bailey
    Life and Health Sciences, Aston University, Birmingham, UK
    Diabetes Obes Metab 14:951-9. 2012
    ..Dapagliflozin, a sodium-glucose co-transporter-2 inhibitor, has shown efficacy in reducing diabetic hyperglycaemia. This study assessed efficacy of three lower doses in recently diagnosed patients...
  8. pmc Functional enhancement of electrofusion-derived BRIN-BD11 insulin-secreting cells after implantation into diabetic mice
    E L Davies
    School of Life and Health Sciences, Aston University, Birmingham, UK
    Int J Exp Diabetes Res 2:29-36. 2001
    ....
  9. ncbi request reprint Glucosamine-induced insulin resistance in L6 muscle cells
    C J Bailey
    School of Life and Health Sciences, Aston University, Birmingham, UK
    Diabetes Obes Metab 6:293-8. 2004
    ..Glucosamine increases flux through the hexosamine pathway, causing insulin resistance and disturbances similar to diabetic glucose toxicity...
  10. ncbi request reprint Avandamet: combined metformin-rosiglitazone treatment for insulin resistance in type 2 diabetes
    C J Bailey
    School of Life and Health Sciences, Aston University, Birmingham, UK
    Int J Clin Pract 58:867-76. 2004
    ..In summary, Avandamet is a single-tablet metformin-rosiglitazone combination that doubly targets insulin resistance as therapy for hyperglycaemia and vascular risk in type 2 diabetes...
  11. ncbi request reprint Earlier intervention in type 2 diabetes: the case for achieving early and sustained glycaemic control
    C J Bailey
    Aston University, Birmingham, UK
    Int J Clin Pract 59:1309-16. 2005
    ....
  12. ncbi request reprint Drugs on the horizon for diabesity
    Clifford J Bailey
    Diabetes Group, Life and Health Sciences, Aston University, Aston Triangle, Birmingham B4 7ET, UK
    Curr Diab Rep 5:353-9. 2005
    ..Many novel antidiabetic and antiobesity compounds are emerging in preclinical development...
  13. doi request reprint Renal glucose reabsorption inhibitors to treat diabetes
    Clifford J Bailey
    Life and Health Sciences, Aston University, Birmingham B4 7ET, UK
    Trends Pharmacol Sci 32:63-71. 2011
    ..The mechanism is independent of insulin and carries a low risk of hypoglycaemia. This review examines the potential of SGLT2 inhibitors as a novel approach to the treatment of hyperglycaemia in T2DM...
  14. ncbi request reprint Rosiglitazone/metformin fixed-dose combination compared with uptitrated metformin alone in type 2 diabetes mellitus: a 24-week, multicenter, randomized, double-blind, parallel-group study
    Clifford J Bailey
    Aston University, Aston Triangle, Birmingham, UK
    Clin Ther 27:1548-61. 2005
    ..Studies have reported the benefits of adding a thiazolidinedione to metformin (MET), but none has compared the effect of adding a thiazolidinedione to MET versus increasing the daily dose of MET to 3 g...
  15. ncbi request reprint Treating insulin resistance: future prospects
    Clifford J Bailey
    Deabetes Research Group, School of Life and Health Sciences, Aston University, Birmingham, B4 7ET, UK
    Diab Vasc Dis Res 4:20-31. 2007
    ..Since insulin resistance affects many metabolic and cardiovascular diseases, it provides an opportunity for simultaneous therapeutic attack on a broad front...
  16. doi request reprint Fixed-dose single tablet antidiabetic combinations
    C J Bailey
    School of Life and Health Sciences, Aston University, Birmingham, UK
    Diabetes Obes Metab 11:527-33. 2009
    ..Anticipated future expansion of multiple drug regimens for diabetes management is likely to increase the use of fixed-dose single tablet combinations...
  17. ncbi request reprint New therapies for diabesity
    Clifford J Bailey
    Life and Health Sciences, Aston University, Aston Street, Aston Triangle, Birmingham B4 7ET, UK
    Curr Diab Rep 9:360-7. 2009
    ..Selective peroxisome proliferator-activated receptor modulators are being studied to produce compounds with desired effects. Many other agents with antidiabetic and antiobesity activity are progressing in clinical development...
  18. doi request reprint What are the practical implications for treating diabetes in light of recent evidence? Updated recommendations from the Global Partnership for Effective Diabetes Management
    Clifford J Bailey
    Diabetes Research, Life and Health Sciences, Aston University, Birmingham B4 7ET, UK
    Diab Vasc Dis Res 6:283-7. 2009
    ....
  19. doi request reprint Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial
    Clifford J Bailey
    Life and Health Sciences, Aston University, Birmingham, UK
    Lancet 375:2223-33. 2010
    ..We assessed the efficacy and safety of dapagliflozin in patients who have inadequate glycaemic control with metformin...
  20. ncbi request reprint Future therapies
    Clifford J Bailey
    School of Pharmacy, Aston University, Birmingham, UK
    Curr Med Res Opin 18:s82-8. 2002
    ..Gene therapy approaches to replace defective or destroyed beta-cells are feasible future options for both type 1 and type 2 diabetes...
  21. doi request reprint Fixed-dose combination therapy for type 2 diabetes: sitagliptin plus pioglitazone
    Clifford J Bailey
    Aston University, Department of Life and Health Sciences, Birmingham, UK
    Expert Opin Investig Drugs 19:1017-25. 2010
    ..The former component acts mainly to increase prandial insulin secretion; the latter improves insulin sensitivity...
  22. doi request reprint Patient adherence to medication requirements for therapy of type 2 diabetes
    C J Bailey
    School of Life and Health Sciences, Aston University, Birmingham, UK
    Int J Clin Pract 65:314-22. 2011
    ..This review explores these factors and potential strategies to improve adherence in patients with type 2 diabetes...
  23. doi request reprint Management of type 2 diabetes: new and future developments in treatment
    Abd A Tahrani
    Centre of Endocrinology, Diabetes and Metabolism, University of Birmingham, Birmingham, UK
    Lancet 378:182-97. 2011
    ..Early proof of principle has been shown for compounds that enhance and partly mimic insulin action and replicate some effects of bariatric surgery...
  24. doi request reprint Palmitate promotes monocyte atherogenicity via de novo ceramide synthesis
    Dan Gao
    School of Life and Health Sciences, Aston University, Birmingham B4 7ET, UK
    Free Radic Biol Med 53:796-806. 2012
    ..Palmitate increases monocyte adhesion to the aortic wall and promotes uptake of oxidized LDL and this involves de novo ceramide synthesis...
  25. doi request reprint Oleate protects against palmitate-induced insulin resistance in L6 myotubes
    Dan Gao
    School of Life and Health Sciences, Aston University, Birmingham, UK
    Br J Nutr 102:1557-63. 2009
    ..Thus, the prevention of palmitate-induced insulin resistance by oleate in L6 muscle cells is associated with the ability of oleate to maintain insulin signalling through PI3-kinase...
  26. ncbi request reprint Potential new treatments for type 2 diabetes
    C J Bailey
    School of Life and Health Sciences, Aston University, Birmingham, UK B4
    Trends Pharmacol Sci 21:259-65. 2000
    ..Clearly, there is a need for new antidiabetic agents...
  27. doi request reprint Metabolic memory effect of the saturated fatty acid, palmitate, in monocytes
    Dan Gao
    School of Life and Health Sciences, Aston University, Birmingham, B4 7ET, UK
    Biochem Biophys Res Commun 388:278-82. 2009
    ..Basal glucose uptake was unaffected by palmitate. When palmitate was washed out, the inhibitory effect on insulin-stimulated glucose uptake persisted for at least 60 h...
  28. doi request reprint SGLT inhibitors in management of diabetes
    Abd A Tahrani
    Centre of Endocrinology, Diabetes and Metabolism, School of Clinical and Experimental Medicine, University of Birmingham, Birmingham, UK Department of Diabetes and Endocrinology, Heart of England NHS Foundation Trust, Birmingham, UK
    Lancet Diabetes Endocrinol 1:140-51. 2013
    ..SGLT inhibition might also be considered in conjunction with insulin therapy in type 1 diabetes. ..
  29. ncbi request reprint New pharmacologic agents for diabetes
    C J Bailey
    Department of Pharmaceutical Sciences, Aston University, Aston Triangle, Birmingham B4 7ET, UK
    Curr Diab Rep 1:119-26. 2001
    ..Direct stimulants of glucose utilization and partial inhibitors of gluconeogenesis are providing useful new drug templates. Thus, new pharmacologic approaches are emerging to treat the multiple lesions of type 2 diabetes...
  30. ncbi request reprint Delta opioid receptors mediate glucose uptake in skeletal muscles of lean and obese-diabetic (ob/ob) mice
    A A Evans
    Department of Physiology, Medical School, University of Birmingham, Birmingham, UK
    Metabolism 50:1402-8. 2001
    ..Thus, glucose transport in skeletal muscle may be partly mediated via delta1-opioid receptors. The increased receptor density in obese-diabetic mice may be an adaptive response...
  31. ncbi request reprint Acute stimulation of glucose uptake by leptin in l6 muscle cells
    S H Bates
    School of Life and Health Sciences, Aston University, Birmingham, UK
    Horm Metab Res 34:111-5. 2002
    ..The results suggest that leptin can act directly on L6 muscle cellsvia a short leptin receptor isoform to acutely stimulate basal (but not insulin-stimulated) glucose uptake via a PI3K-dependent pathway...
  32. ncbi request reprint Differential effects of metformin on bile salt absorption from the jejunum and ileum
    D Carter
    School of Pharmacy, Aston University, Birmingham, UK
    Diabetes Obes Metab 5:120-5. 2003
    ..As bile salts contribute significantly to cholesterol homeostasis, this study has investigated the effect of metformin on the absorption of bile salts by the jejunum and ileum, and their transfer into bile...
  33. pmc Effect of metformin on glucose metabolism in the splanchnic bed
    C J Bailey
    Department of Pharmaceutical Sciences, Aston University, Birmingham
    Br J Pharmacol 105:1009-13. 1992
    ..The results support the view that metformin increased intestinal glucose utilization and lactate production by the intestine. Under basal conditions there was net extraction of lactate by the liver but not after an enteral glucose load...
  34. ncbi request reprint Lipoic acid increases glucose uptake by skeletal muscles of obese-diabetic ob/ob mice
    R C Eason
    School of Pharmacy, Aston University, Birmingham, UK
    Diabetes Obes Metab 4:29-35. 2002
    ..This study has examined the effect of alpha-lipoic acid on glucose uptake by cultured L6 muscle cells and different types of skeletal muscles in normal lean (+/+) and severely insulin-resistant, obese-diabetic (ob/ob) mice...
  35. ncbi request reprint Fenofibrate and cardiovascular risk: a synopsis and commentary on (FIELD)
    C J Bailey
    Aston University, Birmingham, UK
    Diabet Med 23:109-12. 2006
  36. ncbi request reprint Dipeptidyl peptidase IV (DPP IV) and related molecules in type 2 diabetes
    Peter R Flatt
    School of Biomedical Sciences, University of Ulster, Coleraine, UK
    Front Biosci 13:3648-60. 2008
    ..Here we examine the information available on DPP IV and related enzymes, review recent preclinical and clinical data for DPP IV inhibitors, and assess their clinical significance...
  37. pmc Enhanced cAMP generation and insulin-releasing potency of two novel Tyr1-modified enzyme-resistant forms of glucose-dependent insulinotropic polypeptide is associated with significant antihyperglycaemic activity in spontaneous obesity-diabetes
    Victor A Gault
    School of Biomedical Sciences, University of Ulster, Cromore Road, Coleraine BT52 1SA, Northern Ireland, UK
    Biochem J 367:913-20. 2002
    ....
  38. ncbi request reprint Learning from tesaglitazar
    Clifford J Bailey
    Diab Vasc Dis Res 4:161-2. 2007
  39. ncbi request reprint Metabolic stability, receptor binding, cAMP generation, insulin secretion and antihyperglycaemic activity of novel N-terminal Glu9-substituted analogues of glucagon-like peptide-1
    Brian D Green
    School of Biomedical Sciences, University of Ulster, Coleraine BT52 1SA, Northern Ireland, UK
    Biol Chem 384:1543-51. 2003
    ..These observations indicate the importance of Glu9 for the biological activity of GLP-1 and susceptibility to DPP IV-mediated degradation...
  40. ncbi request reprint Oral antidiabetic agents: current role in type 2 diabetes mellitus
    Andrew J Krentz
    Southampton University Hospitals NHS Trust, Southampton, UK
    Drugs 65:385-411. 2005
    ..However, intensive lifestyle intervention can be more effective than drug therapy, at least in the setting of interventional clinical trials. No antidiabetic drugs are presently licensed for use in prediabetic individuals...
  41. ncbi request reprint Degradation, insulin secretion, and antihyperglycemic actions of two palmitate-derivitized N-terminal pyroglutamyl analogues of glucose-dependent insulinotropic polypeptide
    Nigel Irwin
    School of Biomedical Sciences, University of Ulster, Coleraine BT52 1SA, UK
    J Med Chem 48:1244-50. 2005
    ..These data indicate that palmitate-derivitized analogues of N-terminal pyroglutamyl GIP represent a novel class of stable, long-acting, and effective GIP analogues for potential type 2 diabetes therapy...
  42. ncbi request reprint A novel, long-acting agonist of glucose-dependent insulinotropic polypeptide suitable for once-daily administration in type 2 diabetes
    Nigel Irwin
    School of Biomedical Sciences, University of Ulster, Coleraine, Northern Ireland, UK
    J Pharmacol Exp Ther 314:1187-94. 2005
    ....
  43. ncbi request reprint Chemical ablation of gastric inhibitory polypeptide receptor action by daily (Pro3)GIP administration improves glucose tolerance and ameliorates insulin resistance and abnormalities of islet structure in obesity-related diabetes
    Victor A Gault
    School of Biomedical Sciences, University of Ulster, Coleraine, Northern Ireland BT52 1SA, UK
    Diabetes 54:2436-46. 2005
    ..These studies highlight a role for GIP in obesity-related glucose intolerance and emphasize the potential of specific GIP-R antagonists as a new class of drugs for the alleviation of insulin resistance and treatment of type 2 diabetes...
  44. ncbi request reprint Antagonistic effects of two novel GIP analogs, (Hyp3)GIP and (Hyp3)GIPLys16PAL, on the biological actions of GIP and longer-term effects in diabetic ob/ob mice
    Finbarr P M O'Harte
    School of Biomedical Sciences, University of Ulster, Coleraine, BT52 1SA, Northern Ireland
    Am J Physiol Endocrinol Metab 292:E1674-82. 2007
    ..Acylation of (Hyp(3))GIP to extend bioactivity does not appear to be of any additional benefit...
  45. ncbi request reprint Whence and whither the fixed-dose combination?
    Clifford J Bailey
    Diab Vasc Dis Res 2:51-3. 2005
  46. ncbi request reprint GIP(Lys16PAL) and GIP(Lys37PAL): novel long-acting acylated analogues of glucose-dependent insulinotropic polypeptide with improved antidiabetic potential
    Nigel Irwin
    School of Biomedical Sciences, University of Ulster, Coleraine, Northern Ireland, U K
    J Med Chem 49:1047-54. 2006
    ..These data demonstrate that fatty acid derivatized GIP peptides represent a novel class of long-acting stable GIP analogues for therapy of type 2 diabetes...
  47. ncbi request reprint Novel glucagon-like peptide-1 (GLP-1) analog (Val8)GLP-1 results in significant improvements of glucose tolerance and pancreatic beta-cell function after 3-week daily administration in obese diabetic (ob/ob) mice
    Brian D Green
    School of Biomedical Sciences, University of Ulster, Coleraine BT52 1SA, Northern Ireland, UK
    J Pharmacol Exp Ther 318:914-21. 2006
    ..2-fold without changing the number of islets, resulting in an increased number of larger islets. These data demonstrate that (Val8)GLP-1 is more effective and longer acting than native GLP-1 in obese-diabetic ob/ob mice...
  48. ncbi request reprint Inhibition of dipeptidylpeptidase IV activity as a therapy of type 2 diabetes
    Brian D Green
    Queens University Belfast, School of Biological Sciences, David Keir Building, Stranmillis Road, Belfast BT9 5AG, Northern Ireland
    Expert Opin Emerg Drugs 11:525-39. 2006
    ..If long-term clinical trials confirm sustained and safe control of blood glucose, DPP IV inhibitors (known as 'gliptins') may be expected to provide a new treatment modality for Type 2 diabetes...
  49. ncbi request reprint Early and intensive treatment: Glycaemic control in type 2 diabetes
    Clifford J Bailey
    Diab Vasc Dis Res 3:145-6. 2006
  50. ncbi request reprint Dipeptidyl peptidase IV (DPP IV) inhibitors: A newly emerging drug class for the treatment of type 2 diabetes
    Brian D Green
    School of Biological Sciences, Queens University Belfast, Belfast, BT9 5AG, UK
    Diab Vasc Dis Res 3:159-65. 2006
    ..In clinical trials DPP IV inhibitors (or 'gliptins') have shown efficacy and tolerability in the management of hyperglycaemia in type 2 diabetes, without causing weight gain or hypoglycaemia...
  51. ncbi request reprint The sibutramine metabolite M2 improves muscle glucose uptake and reduces hepatic glucose output: preliminary data
    Dawn K Coletta
    Division of Diabetes, Department of Medicine, The University of Texas Health Science Center at San Antonio, San Antonio, Texas 78229 3900, USA
    Diab Vasc Dis Res 3:186-8. 2006
    ..05). These preliminary results suggest that the M2 metabolite of sibutramine can reduce glycaemia, maintain insulin-mediated muscle glucose uptake and reduce hepatic gluconeogenesis independently of satiety and weight loss...
  52. ncbi request reprint Metformin and its liver targets in the treatment of type 2 diabetes
    Jerry Radziuk
    Department of Medicine, Ottawa Hospital and University of Ottawa, ON, Canada
    Curr Drug Targets Immune Endocr Metabol Disord 3:151-69. 2003
    ....
  53. ncbi request reprint Insulin-stimulated endothelial nitric oxide release is calcium independent and mediated via protein kinase B
    Nicholas A Hartell
    Department of Pharmacology, The School of Pharmacy, University of London, WC1N 1AX, UK
    Biochem Pharmacol 69:781-90. 2005
    ..Insulin-stimulated NO production by endothelium is an acute calcium-independent effect mediated via the PI3K-PKB signalling pathway...
  54. ncbi request reprint Antidiabetic potential of two novel fatty acid derivatised, N-terminally modified analogues of glucose-dependent insulinotropic polypeptide (GIP): N-AcGIP(LysPAL16) and N-AcGIP(LysPAL37)
    Nigel Irwin
    School of Biomedical Sciences, University of Ulster, Coleraine, BT52 1SA, N Ireland, UK
    Biol Chem 386:679-87. 2005
    ..These data demonstrate that novel fatty acid-derivatised analogues of N-terminally modified AcGIP function as long-acting GIP-receptor agonists, with significant antidiabetic potential...
  55. ncbi request reprint Cardio-diabetes alliances
    Clifford J Bailey
    Diab Vasc Dis Res 4:6-7. 2007